BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33132436)

  • 1. Identification of cisplatin-resistant factor by integration of transcriptomic and proteomic data using head and neck carcinoma cell lines.
    Inukai D; Nishimura K; Okamoto H; Sano R; Ueda H; Ota A; Karnan S; Hosokawa Y; Yoshikawa K; Suzuki S; Ueda R; Murotani K; Bradford CR; Ogawa T
    Nagoya J Med Sci; 2020 Aug; 82(3):519-531. PubMed ID: 33132436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
    Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
    Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.
    Syed N; Chavan S; Sahasrabuddhe NA; Renuse S; Sathe G; Nanjappa V; Radhakrishnan A; Raja R; Pinto SM; Srinivasan A; Prasad TS; Srikumar K; Gowda H; Santosh V; Sidransky D; Califano JA; Pandey A; Chatterjee A
    Proteomics; 2015 Jan; 15(2-3):383-93. PubMed ID: 25327479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells.
    Khera N; Rajkumar AS; Abdulkader M Alkurdi K; Liu Z; Ma H; Waseem A; Teh MT
    Mol Cancer; 2023 Sep; 22(1):146. PubMed ID: 37667354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma.
    Yamano Y; Uzawa K; Saito K; Nakashima D; Kasamatsu A; Koike H; Kouzu Y; Shinozuka K; Nakatani K; Negoro K; Fujita S; Tanzawa H
    Int J Cancer; 2010 Jan; 126(2):437-49. PubMed ID: 19569180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
    Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
    Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
    Lee J; Park M; Ko Y; Kim B; Kim O; Hyun H; Kim D; Sohn H; Moon YL; Lim W
    Tumour Biol; 2017 Apr; 39(4):1010428317695534. PubMed ID: 28381190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
    Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
    Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
    Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
    Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
    Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
    Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry.
    Theile D; Detering JC; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Burhenne J
    J Pharmacol Exp Ther; 2012 Apr; 341(1):51-8. PubMed ID: 22207655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CD147 contributes to the chemoresistance of head and neck squamous cell carcinoma cells.
    Huang Z; Wang L; Wang Y; Zhuo Y; Li H; Chen J; Chen W
    J Oral Pathol Med; 2013 Aug; 42(7):541-6. PubMed ID: 23413783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
    Govindan SV; Kulsum S; Pandian RS; Das D; Seshadri M; Hicks W; Kuriakose MA; Suresh A
    Mol Med Rep; 2015 Aug; 12(2):3025-32. PubMed ID: 25962396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome.
    Marimuthu A; Chavan S; Sathe G; Sahasrabuddhe NA; Srikanth SM; Renuse S; Ahmad S; Radhakrishnan A; Barbhuiya MA; Kumar RV; Harsha HC; Sidransky D; Califano J; Pandey A; Chatterjee A
    Biochim Biophys Acta; 2013 Nov; 1834(11):2308-16. PubMed ID: 23665456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma.
    Gao J; Zhao S; Halstensen TS
    Oncol Rep; 2016 Jun; 35(6):3265-74. PubMed ID: 27108527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.